Establishes a generic drug research and development laboratory and production facility to manufacture generic prescription drugs in the state and the empire state biosimilar insulin initiative, which will develop generic forms of the three most widely used forms of insulin.

This bill aims to create a laboratory and production facility in New York for developing and manufacturing generic prescription drugs. It specifically focuses on producing generic versions of the three most commonly used types of insulin, making these essential medications more accessible to patients.

Supporters of the bill would highlight its potential to lower the cost of prescription drugs, particularly insulin, by increasing competition in the market. They would argue that this initiative promotes public health and ensures that more people can afford necessary medications.

Critics might argue that establishing a state-run facility could lead to inefficiencies and increased government spending. They may also raise concerns about the quality and safety of drugs produced in a government lab compared to those made by established pharmaceutical companies.